Delix Therapeutics, an American biotech firm, was founded with the mission to revolutionize brain health therapeutics by developing non-hallucinogenic psychedelic therapies. The company focuses on harnessing neuroplastogens, a novel class of compounds that promote neuroplasticity, to create safe, fast-acting, and long-lasting treatments for mental health conditions. Delix's innovative approach aims to leverage the brain's natural ability to grow and form connections, offering a new paradigm in pharmaceutical development.

Notable figures associated with Delix Therapeutics include leading neuroscientists and pharmaceutical experts who have contributed to its pioneering research. The company has garnered significant attention and investment from prominent venture capital firms in the biotech sector. Key achievements include the identification and development of neuroplastogens with favorable safety and therapeutic profiles, positioning Delix as a leader in the next generation of mental health treatments. The impact of Delix's work promises to transform the landscape of psychiatric care by providing effective alternatives to traditional therapies.